Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
125
resultados
Última actualización
13/08/2025 [07:11:00]
Resumen de: US2025250254A1
A compound represented by formula (I) or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof are provided. In formula (I), R1-R17 are each independently selected from hydrogen and deuterium, R18 and R19 are hydrogen, and R1-R19 are not simultaneously hydrogen. The deuterated compound and the salt, hydrate or solvate thereof have excellent metabolic stability and pharmacokinetic properties, and can be used in the manufacture of tubulin inhibitors, anti-cancer drugs, antiviral drugs, and drugs for the treatment of novel coronavirus pneumonia.
Resumen de: WO2025166067A1
Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of SARS-CoV-2; and (ii) a complement binding polypeptide. The disclosure also provides polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.
Resumen de: WO2025164815A1
The present invention relates to a novel peptide having binding affinity to ACE2 and uses thereof and, more specifically, to: a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4, and having binding affinity to ACE2; a nanocarrier and a drug complex, each comprising the peptide; and a pharmaceutical composition for preventing or treating COVID-19, comprising the peptide, the nanocarrier, or the drug complex. The novel peptide according to the present invention can be used to increase the COVID-19 therapeutic effect through specific binding to ACE2-expressing cells.
Resumen de: WO2025163362A1
The proposed invention, which combines cellulose acetate nanofibers with hyssop essential oil, offers a unique approach by integrating both advanced filtration technology and natural antiviral agents. This dual functionality sets it apart from existing patents, potentially providing enhanced protection against airborne pathogens while maintaining breathability and comfort.
Resumen de: WO2025162130A1
The present invention relates to the field of pharmacological research, and specifically relates to a compound as shown in general formula (I), or a pharmaceutically acceptable salt, tautomer, enantiomer, diastereomer, racemate, hydrate, ester, solvate, metabolic precursor or prodrug thereof, a preparation method therefor, a pharmaceutical combination comprising same, and a use of the compound in the prevention and/or treatment of respiratory diseases caused by viruses (such as SARS-CoV2, SARS-CoV, and MERS-CoV) and in the inhibition of nonstructural proteins of the related viruses, such as a papain-like protease protein.
Resumen de: AU2024225919A1
The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.
Resumen de: AU2025205555A1
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject. Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject. ul u l i s c l o s e d h e r e i n a r e n u c l e i c a c i d m o l e c u l e s e n c o d i n g a e v e r e c u t e e s p i r a t o r y y n d r o m e c o r o n a v i r u s ( - o - ) s p i k e a n t i g e n , - o - s p i k e a n t i g e n s , i m m u n o g e n i c c o m p o s i t i o n s , a n d v a c c i n e s a n d t h e i r u s e i n i n d u c i n g i m m u n e r e s p o n s e s a n d p r o t e c t i n g a g a i n s t o r t r e a t i n g a - o - i n f e c t i o n i n a s u b j e c t
Resumen de: AU2023411024A1
Disclosed herein are compositions comprising a Siglec-9 inhibitor, a fragment thereof, a variant thereof, or a combination thereof, and methods of use thereof for enhancing an immune response. Also disclosed herein is a therapeutic composition comprising a combination of Siglec-9 inhibitor and an anti-SARS-CoV-2 antibody, or a bispecific anti- Siglec-9/anti-SARS-CoV-2 antibodies and methods of use for treating or preventing COVID- 19.
Resumen de: US2025249089A1
Recombinant plasmids and immunogenic DNA compositions including a recombinant plasmid which carries the gene sequence encoding the Spike protein or the gene sequence encoding the NP protein, with the capacity to prevent high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system, both against the ancestral strain of SARS-CoV-2 and influenza strains against different variants of concern that are currently circulating are disclosed. A bivalent recombinant plasmid and a immunogenic composition including the bivalent recombinant plasmid which carries the gene sequence encoding the NP and Spike protein, with the capacity to prevent high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system, both against the influenza strain and SARS-COV-2 strain against different variants of concern that are currently circulating are disclosed.
Resumen de: US2025249088A1
Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.
Resumen de: US2025248965A1
Compounds for use against a viral infection The invention relates to hexahydronaphthalen-2-one derivatives, such as petasol, petasin and isopetasol, for use in the prevention or the treatment of viral infections. In particular compounds extracted from Darksidea spp. are provided for use in the treatment of SARS-CoV-2 infection.
Resumen de: US2025250647A1
Coronavirus genomes comprising non-native SARS-CoV-2 RNAs having genetically inactivated spike (S), envelope (E), and membrane (M) genes, and optionally a genetically inactivated nucleocapsid (NP) gene, are provided. Such coronavirus genomes further include a reporter gene and a marker gene, and substitutions within a non-structural protein 1 (Nsp1) gene (such as K164A and H165A). Also provided are cells containing the coronavirus genomes, for example, stable cell clones having the isolated non-native coronavirus genome autonomously replicating inside the cells. Also provided are methods of using such cells, for example, methods of identifying anti-viral compounds, such as quantitative high-throughput screening methods that can optionally be performed in a biosafety level 2 (BSL2) laboratory.
Resumen de: US2025250312A1
A bifunctional peptide is provided, the bifunctional peptide comprising a virus binding moiety and a mucin binding moiety covalently bound to the virus binding moiety. The virus binding moiety is chosen from peptides binding to SARS-CoV-2, to influenza A, to influenza B, to rhinoviruses and other enteroviruses, to human parainfluenza virus, and/or to metapneuvirus. The mucin binding moiety is chosen from lectins such as trefoil factor 3.
Resumen de: AU2023412579A1
An application of shenling baizhu in the preparation of a drug for treating psychoneurological symptoms of recovered COVID-19 patients.
Resumen de: WO2024068265A2
The present invention relates to the use of vaccines comprising virus-like particles displaying at least one SARS-CoV-2 antigen, such as the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, as vaccine boosters. Antigens are displayed on virus-like particles (VLPs) and produce an immune response in vaccinated subjects. The invention also relates to methods of treatment using the recombinant VLPs as boosters to treat and/or prevent infection with SARS-CoV-2, and methods of preparation thereof.
Resumen de: CN120051481A
The invention discloses a phage for specifically capturing SARS-CoV-2 virus, the phage is an engineered M13 phage, so that an FGKGGYEKTWKLGD sequence peptide or an EFTSKAR sequence peptide is displayed on a P8 protein of a shell of the phage, and the peptide has specific affinity to a spike S1 protein of the SARS-CoV-2 virus.
Resumen de: WO2024068777A1
The present invention relates to therapeutic proteins and medical uses thereof. The present invention relates to modified ACE2 protein having increased binding affinity for the SARS- CoV-2 spike protein compared to wildtype ACE2 protein, wherein said modified ACE2 protein is lacking enzymatic activity and is fused to (i) a modified Fc domain of human immunoglobulin, wherein the Fc domain has either enhanced immunostimulating activity (Fc+) or attenuated immunostimulating activity (Fc-) or (ii) a protein that specifically binds to T cells or further enhances immunostimulating activity. The invention also relates to a polynucleotide encoding the modified ACE2 protein of the present invention, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct, and a non-human transgenic organism comprising the polynucleotide or the vector or expression construct. Moreover, the present invention relates also to a method for the manufacture of a modified ACE protein according to the present invention and to a medicament comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention. Furthermore, the invention relates to medical uses of the modified ACE2 protein, the polynucleotide or the vector or expression construct in treating and/or preventing a disease or disorder associated with SARS-CoV-2 infection. Finally, the invention provides a kit comprising th
Resumen de: LU508111B1
The invention belongs to the field of biotechnology, and specifically discloses a method for analyzing an influence of COVID-19 on a tuberculosis patient and a possible drug based on system biology and bioinformatics, which comprises the following steps of: 10 (1) carrying out differential expressed gene analysis on two PBMC data sets of COVID-19 and tuberculosis to obtain two sets of differential expressed genes, and intersecting the two sets of differential expressed genes to obtain common differential expressed genes; (2) constructing a protein-protein interaction network, which is a PPI network, according to the common differential expressed genes in the step (1); and analyzing and selecting hub 15 genes for the PPI network; and (3) carrying out drug prediction according to the hub genes determined in the step (2) by using an enrichr platform, and selecting a drug capable of treating COVID-19 and tuberculosis at the same time.
Resumen de: MX2025007248A
An application of shenling baizhu in the preparation of a drug for treating psychoneurological symptoms of recovered COVID-19 patients.
Resumen de: MX2025002237A
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: MX2025005412A
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
Resumen de: US2025242013A1
The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.
Resumen de: US2025243282A1
Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
Resumen de: US2025242059A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Nº publicación: US2025241978A1 31/07/2025
Solicitante:
APEPTICO FORSCHUNG UND ENTW GMBH [AT]
APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
Resumen de: US2025241978A1
A peptide for prevention and treatment of COVID-19 in a patient, wherein the peptide consists of 7-17 amino acids and includes the hexamer TX1EX2X3E, wherein X1, X2 and X3 can be any natural or non-natural amino acid, and wherein the peptide does not exhibit TNF-receptor-binding activity. Suitable peptides include solnatide (cyclo-CGQRETPEGAEAKPWYC).
BOPI
Sede Electrónica
